- $176.43bn
- $229.78bn
- $28.19bn
- 87
- 22
- 92
- 74
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 16.06 | ||
PEG Ratio (f) | 1.33 | ||
EPS Growth (f) | 13.69% | ||
Dividend Yield (f) | 2.98% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 29.78 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 32.19 | ||
Price to Sales | 5.7 | ||
EV to EBITDA | 19.96 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 9.28% | ||
Return on Equity | 49.27% | ||
Operating Margin | 20.81% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 23,362 | 25,424 | 25,979 | 26,323 | 28,190 | 33,196.51 | 34,194.88 | 3.49% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -0.5 | -4.88 | +4.87 | +0.05 | -2.83 | +55.25 | +6.29 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Directors
- Robert Bradway CHM (58)
- Peter Griffith CFO (62)
- Jonathan Graham EVP (60)
- Lori Johnston EVP (56)
- Murdo Gordon EVP (54)
- David Reese EVP (58)
- Esteban Santos EVP (53)
- David Piacquad SVP (64)
- Robert Eckert LED (66)
- Wanda Austin IND (66)
- Brian Druker IND (65)
- Gregory Garland IND (63)
- Charles Holley IND (64)
- S. Omar Ishrak IND
- Tyler Jacks IND (60)
- Ellen Kullman IND (65)
- Amy Miles IND (54)
- Ronald Sugar IND (73)
- Robert Williams IND (72)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- October 31st, 1986
- Public Since
- June 17th, 1983
- No. of Shareholders
- 4,614
- No. of Employees
- 26,700
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 537,329,220
- Address
- One Amgen Center Drive, THOUSAND OAKS, 91320
- Web
- https://www.amgen.com/
- Phone
- +1 8054471000
- Auditors
- Ernst & Young LLP
Latest News for AMGN
Upcoming Events for AMGN
Q3 2024 Amgen Inc Earnings Release
Q3 2024 Amgen Inc Earnings Call
Q4 2024 Amgen Inc Earnings Release
Similar to AMGN
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 13:15 UTC, shares in Amgen are trading at $328.35. This share price information is delayed by 15 minutes.
Shares in Amgen last closed at $328.35 and the price had moved by +15.19% over the past 365 days. In terms of relative price strength the Amgen share price has underperformed the S&P500 Index by -14.27% over the past year.
The overall consensus recommendation for Amgen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Amgen dividend yield is 2.67% based on the trailing twelve month period.
Last year, Amgen paid a total dividend of $8.76, and it currently has a trailing dividend yield of 2.67%. We do not have any data on when Amgen is to next pay dividends.
We do not have data on when Amgen is to next pay dividends. The historic dividend yield on Amgen shares is currently 2.67%.
To buy shares in Amgen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $328.35, shares in Amgen had a market capitalisation of $176.43bn.
Here are the trading details for Amgen:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AMGN
Based on an overall assessment of its quality, value and momentum Amgen is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Amgen is $331.68. That is 1.01% above the last closing price of $328.35.
Analysts covering Amgen currently have a consensus Earnings Per Share (EPS) forecast of $19.49 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amgen. Over the past six months, its share price has outperformed the S&P500 Index by +6.94%.
As of the last closing price of $328.35, shares in Amgen were trading +7.59% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Amgen PE ratio based on its reported earnings over the past 12 months is 16.06. The shares last closed at $328.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Amgen's management team is headed by:
- Robert Bradway - CHM
- Peter Griffith - CFO
- Jonathan Graham - EVP
- Lori Johnston - EVP
- Murdo Gordon - EVP
- David Reese - EVP
- Esteban Santos - EVP
- David Piacquad - SVP
- Robert Eckert - LED
- Wanda Austin - IND
- Brian Druker - IND
- Gregory Garland - IND
- Charles Holley - IND
- S. Omar Ishrak - IND
- Tyler Jacks - IND
- Ellen Kullman - IND
- Amy Miles - IND
- Ronald Sugar - IND
- Robert Williams - IND